Engram-Edge generates advanced 3D human brain organoids from patient-specific induced pluripotent stem cells (iPSCs) — enabling neuropsychiatric disease modeling and drug screening that actually translates to patients.
> model: cortical organoid, 60d maturation
> assay: Ca² imaging, patch-clamp, RNA-seq
> application: ASD · schizophrenia · neurodegeneration
CNS drug development faces a >90% attrition rate — largely because animal models fail to recapitulate the genetic and cellular complexity of the human brain. This gap costs billions in failed clinical trials and delays treatments for millions of patients.
At Engram-Edge, we replace that gap with patient-derived 3D brain organoids that mirror the structural organization, electrophysiology, and disease-specific genetics of human neural tissue — delivering data that translates.
"Bridging the gap between bench and bedside with human-relevant neuroscience."
Patient-derived brain organoids capture disease-specific genetics across a broad spectrum of neuropsychiatric conditions — from rare syndromes to complex polygenic disorders.
Modeling synaptic connectivity deficits and excitatory/inhibitory imbalances in patient-derived cortical organoids with ASD-associated variants.
NeurodevelopmentalCapturing dopaminergic and glutamatergic signaling dysregulation in human brain organoids derived from schizophrenia patient iPSCs.
NeuropsychiatricRecapitulating amyloid-beta aggregation, tau pathology, and neuroinflammation in 3D cortical organoids to accelerate AD drug discovery.
NeurodegenerativeModeling dopaminergic neuron degeneration and alpha-synuclein pathology using midbrain organoids derived from PD patient-specific iPSCs.
NeurodegenerativeEnabling precision modeling of rare monogenic neurological conditions including Rett syndrome, Timothy syndrome, and Angelman syndrome.
Rare NeurologicalStudying serotonergic and GABAergic circuit dysfunction in organoids to identify biomarkers and test novel antidepressant candidates.
NeuropsychiatricTailored to your research and drug development pipeline.
Custom 3D brain organoids generated from patient-specific iPSCs. Capture disease-relevant genetic backgrounds for truly personalized disease modeling and precision medicine.
Scale your compound screening with our organoid-compatible HTS platform. Evaluate hundreds of candidates with human-relevant readouts in parallel — 96- and 384-well format compatible.
Validate drug candidates in a controlled, reproducible human brain environment before moving to clinical stages. Powered by single-cell resolution and AI-driven analysis.
A streamlined workflow designed to get you results faster.
We obtain iPSCs from patient samples or commercially available engineered variants — cells with the unique ability to differentiate into any cell type for individualized brain models.
Using proprietary cost-effective differentiation methods, we generate 3D human brain organoids that mimic key aspects of neural development and function.
Calcium imaging, patch-clamp electrophysiology, immunofluorescence, and bulk/single-cell RNA sequencing reveal how neurological conditions manifest at cellular resolution.
Candidate compounds are evaluated on organoids to assess effectiveness and safety, reducing dependence on animal models while improving clinical predictions.
Automated image analysis and machine learning generate biomarker signatures, patient-stratification reports, and therapeutic target rankings — delivered via our analytics platform.
Three pillars that set our organoid platform apart from conventional approaches.
Our platform was built with training at Dr. Sergiu Paşca’s lab at Stanford University — one of the world’s leading centers in human brain organoid research. We apply those methods at scale for your projects.
Proprietary, cost-optimized differentiation protocols reduce organoid generation time and cost without compromising biological fidelity — making scalable human-relevant drug screening accessible.
Every assay, every readout, every data point comes from human-derived tissue. Our end-to-end workflow is built around patient cells — so your data is clinically relevant from day one.
Multidisciplinary expertise across stem cell biology, neuroscience, and bioengineering.
Molecular Biotechnology Engineer with dual PhDs in Molecular Biology and Neurosciences (University of Chile & Université Sorbonne Paris Cité). Doctoral and postdoctoral research completed in Paris.
Biochemist with a PhD in Medical Sciences (PUC Chile). Postdoctoral research on neurodevelopment with genetically modified iPSCs. Trained in human brain organoids at Dr. Sergiu Paşca's lab, Stanford University.
PhD in Computer Science (Pontifical Catholic University of Valparaíso), PhD in Complex Systems Engineering (Adolfo Ibáñez University), Molecular Biotechnology Engineer (University of Chile). Expert in machine learning, artificial intelligence, and bioinformatics.
Whether you’re a pharmaceutical company seeking human-relevant drug screening or an academic lab modeling a neuropsychiatric condition — we build the organoid solution for your research.